Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

BAYER (BAYN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Bayer : foundations bring tech pioneers, physicians and social entrepreneurs to the World Health Summit

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/13/2017 | 10:05am CEST

Leverkusen, October 13, 2017- The World Health Summit will be held on October 15-17, 2017, in Berlin under the patronage of German Chancellor Angela Merkel, French President Emmanuel Macron and European Commission President Jean-Claude Juncker. Key topics this year are health policy in the G7/G20, new vaccine research and development, digitalization and big data, health security, urban health, and Africa and the United Nations' sustainability goals. This year's speakers include seven government ministers from six countries, two Nobel laureates, and CEOs of businesses and NGOs - including Werner Baumann, Chairman of the Board of Management of Bayer AG.

The Bayer foundations have been supporting the World Heath Summit since 2014 with financial sponsorship in the form of participant stipends in the Young Physician Leaders (YPL) Program and with subject-matter expertise in dialog events. YPL alumnus Dr. Kalana Maduwage's project is a particularly impressive success story. The physician, scientist, social entrepreneur and snake expert from Sri Lanka took part in the summit last year as a Bayer stipend recipient and garnered enthusiasm with a unique innovation. In his home country alone, around 80,000 farmers are bitten by snakes in their fields every year. The doctors there face a real dilemma: there is never enough antivenom available to treat all of the patients, but anyone receiving treatment too late has little chance of a successful recovery. Maduwage recognized this dilemma from his own work as a physician and is currently working on developing a fast enzyme-based test to determine the actual concentration of snake venom in a patient's blood. In the future, doctors will be able to administer the limited medication in a targeted way and save many patients.

The Bayer Cares Foundation has nominated the project for the 2017 Aspirin Social Innovation Award and will present it, along with other groundbreaking ideas, as part of 'The Beauty of Impact' panel at the World Health Summit 2017. The Bayer foundations' lineup will include the social entrepreneur and founder of Discovering Hands, Dr. Frank Hoffmann, who is training blind women to perform breast examinations, as well as Martin Aufmuth, the founder of OneDollarGlasses, a charitable company that produces spectacles for one dollar, with the goal of enabling everyone all over the world to purchase spectacles when needed.

The entire World Health Summit is open to the media: www.worldhealthsummit.org/media/accreditation

Find more information at: www.bayer-foundations.com

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Bayer AG published this content on 13 October 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 13 October 2017 08:04:09 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER
06/15BAYER : Japan suspends sale of Canadian wheat after GMO wheat found in Alberta
RE
06/15BAYER AKTIENGESELLSCHAFT : Notification and public disclosure of transactions by..
EQ
06/15BAYER AKTIENGESELLSCHAFT : Notification and public disclosure of transactions by..
EQ
06/15BAYER AKTIENGESELLSCHAFT : Notification and public disclosure of transactions by..
EQ
06/14BAYER : Recent Findings from F. Kanefendt and Co-Authors Yields New Data on Phar..
AQ
06/14Bayer begins Rs 1.3K cr offer to buy stake in Monsanto
AQ
06/14BAYER AKTIENGESELLSCHAFT : Notification and public disclosure of transactions by..
EQ
06/13BAYER : Federal Register Extracts
AQ
06/13BAYER AKTIENGESELLSCHAFT : Notification and public disclosure of transactions by..
EQ
06/13BAYER AKTIENGESELLSCHAFT : Notification and public disclosure of transactions by..
EQ
More news
News from SeekingAlpha
06/13Biotech industry group criticized for party featuring topless dancers 
06/11Merck KGaA's tepotinib successful two mid-stage liver cancer studies 
06/093 THINGS IN BIOTECH, JUNE 8 : Ascend Ye PARP Inhibitors 
06/08Risk Aversion Returns Ahead Of Tense G7 Summit; China's US Trade Surplus Jump.. 
06/08WALL STREET BREAKFAST : Risk Sentiment Sours Before G7 Summit 
Financials (€)
Sales 2018 35 560 M
EBIT 2018 7 094 M
Net income 2018 5 068 M
Debt 2018 12 910 M
Yield 2018 2,78%
P/E ratio 2018 18,11
P/E ratio 2019 16,18
EV / Sales 2018 2,99x
EV / Sales 2019 2,72x
Capitalization 93 330 M
Chart BAYER
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Technical analysis trends BAYER
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 116 €
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER-2.22%108 347
JOHNSON & JOHNSON-12.21%328 858
PFIZER-0.17%212 690
NOVARTIS-8.25%193 446
ROCHE HOLDING LTD.-14.06%183 969
MERCK AND COMPANY10.24%166 880